Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Patent
1995-06-05
1998-11-17
Loring, Susan A.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
435325, 435326, 435332, 5303871, 5303882, 5303884, C12N 506, C07K 1600
Patent
active
058375414
ABSTRACT:
Cell lines have been produced that secrete human monoclonal antibodies capable of binding to molecules of different bacterial species. These antibodies have been found to be protective against lethal challenges of various bacterial genera. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal antibodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections are included. Prior to filing of this patent application the continuous transformed human cell lines 9B10, 4F10, 4B9, 7D7, and 9C3, described herein, were deposited in the American Type Culture Collection and given the designations CRL 9006, CRL 9007, CRL 9008, CRL 9009, and CRL 9239, respectively.
REFERENCES:
patent: 4464465 (1984-08-01), Lostrum
patent: 4587121 (1986-05-01), Collins et al.
patent: 4675287 (1987-06-01), Reisfeld
patent: 4677070 (1987-06-01), Larrick et al.
patent: 4734279 (1988-03-01), Stephan
patent: 4772464 (1988-09-01), Rutherford et al.
patent: 4777136 (1988-10-01), Young
patent: 4970070 (1990-11-01), Raff
patent: 5378812 (1995-01-01), Young
patent: 5484591 (1996-01-01), Young
Sevier, E.D. et al, Clin Chem, 27(11):1797-1806, 1981.
Grados et al., "Antigenic Relationship between Escherichia coli and Neisseria meningitidis," J. Infect. Dis. 122:100-103 (1970).
Kasper et al., "Immunochemical Similarity Between Polysaccharide Antigens of Escherichia Coli 07:K1(L) :NM and Group B Neisseria Meningtidis," J. Immunol. 110:262-268 (1973).
Mullan et al., "Protection Against Gram-Negative Infections with Antiserum to Lipid A from Salmonella minnesota R595,"Infect. Immun., 1195-1201 (1974).
Artenstein et al., "Cross-reaction of Meningococcal Group B Polysaccharide and the K1 Polysaccharide Antigen of E. coli 07:K1(L) : NM"in Robbins, J.B. et al. (Eds.), New Approaches for Inducing Natural Immunity to Pyogenic Organisms, NIH, Bethesda, MD, pp. 57-58 (1975).
Robbins et al., "Escherichia coli K1 Antigen Associated with Neonatal Meningitis" in Robbins, J.B., et al. (Eds.), New Approaches for Inducing Natural Immunity to Pyogenic Organisms, NIH, Bethesda, MD, pp. 59-62 (1975).
McCabe et al., "Cross-Reactive Antigens: Their Potential for Immunization-Induced Immunity to Gram-Negative Bacteria," J. Infect. Dis., 136S:161-166 (1977).
Wilkinson, "Composition and Structure of Bacterial Lipopolysaccharides," Surface Carbohydrates of the Prokaryotic Cell pub. Academic Press, Inc., pp. 97-171 (1977).
Sorensen et al., "Defective Cellular Immunity to Gram-Negative Bacteria in Cystic Fibrosis Patients," Infect. Immun., 23:398-402 (Feb. 1979).
Baltimore et al., "Mouse Protection Test for Group B Streptococcus Type III," J. Infect. Dis. 140:81-88 (1979).
Ruch, Jr. et al., "Monoclonal Antibody to Streptococcal Group B Carbohydrate: Applications in Latex Agglutination and Immunoprecipitin Assays," J. Clin. Microbiol. 16:145-152 (1982).
Hiernaux et al., "Study of the Idiotypy of Lipopoly-Saccharide-Specific Polyclonal and Monoclonal Antibodies," Eur. J. Immunol., 12:797-803 (1982).
Moreno et al., "Immunological Properties of Monoclonal Antibodies Specific for Meningococcal Polysaccharides: The Protective Capacity of IgM Antibodies Specific for Polysaccharide Group B," J. Gen. Microbiol., 129:2451-2456 (1983).
Finne et al., "Antigenic Similarities Between Brain Components and Bacteria Causing Meningitis," Lancet 2:355-357 (1983).
Sugasawara et al., "Monoclonal Antibodies Against Neisseria Menigitidis Lipopolysaccharide," Infect. Immun., 42:363-868 (Dec. 1983).
Cross et al., "Evaluation of Immunotherapeutic Approaches for the Potential Treatment of Infections Caused by K1-Positive Escherichia coli," J. Infect. Dis., 147:68-76, (1983).
Soderstrom et al., "Serological and Functional Properties of Monoclonal Antibodies to Escherichia coli Type I Pilus and Capsular Antigens," Prog. Allergy 33:259-274, (1983).
Cross et al., "The Importance of the K1 Capsule In Invasive Infections Caused Escherichia coli," J. Infect. Dis., 149:184-193, (1983).
Egan et al., "Protection of Mice from Experimental Infection with Type III Group B Streptocococcus Using Monoclonal Antibodies," J. Exp. Med., 1:1006-1011 (1983).
Guerina et al., "The Role of Pili and Capsule in the Pathogenesis of Neonatal Infection with Escherichia coli K1," J. Infect. Dis. 148:395-405 (1983).
Zollinger et al., "Importance of Complement Source in Bactericidal Activity of Human Antibody and Murine Monoclonal Antibody to Meningococcal Group B Polysaccharide," Infect. Immun. 40:257-264 (1983).
Collins et al., "Comparative Anti-Pseudomonas aeruginosa Activity of Chemically Modified and Native Immunoglobulin G (Human), and Potentiation of Antibiotic Protection Against Pseudomonas aeruginosa and Group B Streptococcus in Vivo," Am. J. Med. 76:155-160 (1984).
Kirkland et al., "An Immunoprotective Monoclonal Antibody to Lipopolysaccharide," J. Immunol. 132:2590-2592 (1984).
Cryz et al., "Protection Against Fatal Klebsiella pneumoniae Burn Wound Sepsis by Passive Transfer of Anti-capsular Polysaccharide," Infect. Immun. 45:139-142 (1984).
Gigliotti et al., "Reproducible Production of Protective Human Monoclonal Antibodies by Fusion of Peripheral Blood Lymphocytes with a Mouse Myeloma Cell Line," J. Infect. Dis. 149:43-47 (1984).
Hunter, Jr. et al., "Human Monoclonal Antibacterial Antibodies: Protection Against Haemophilus Influenzae Type B By Antibodies to the Capsular Polysaccharide," New Horiz. Microbiology, pp. 99-106 (1984).
Ceriani et al., "An Experimental Model for the Immunological Treatment of Breast Cancer," Proc. Int'l Workshop Monoclonal Antibodies & Breast Cancer, pp. 248-268 (Nov. 8-9, 1984).
Abraham et al., "Protection Against Escherichia coli-Induced Urinary Tract Infections with Hybridoma Antibodies Directed Against Type 1 Fimbriae or Complementary D-Mannose Receptors," Infect. Immun. 48: 625-628 (1985).
Mayer et al., "Analysis of Lipopolysaccharides of Gram-Negative Bacteria," Meths. Microbiology, 18:157-201 (1985).
Shart Sakulramrung et al., "Cross-Reactive Immunoprotective Antibodies to Escherichia coli 0111 Rought Mutant J5," J. Infect. Dis., 151:995-1104 (1985).
Teng et al., "Protection Against Gram-negative Bacteremia and Endotoxemia with Human Monoclonal IgM Antibodies," Proc. Natl. Acad. Sci. USA 82:1790-1794 (1985).
Elkins et al., "Binding Activity of a Murine Anti-Lipid A Monoclonal Antibody," Infect. Immun. 48:597-600 (1985).
Gigliotti et al., "Failure of Monoclonal Antibodies to core Glycolipid to Bind Intact Smooth Strains of Escherichia coli," J. Infect. Dis. 151:1005-1011 (1985).
Frosch et al., "NZB Mouse System for Production of Monoclonal Antibodies to Weak Bacterial Antigens: Isolation of an IgG antibody to the Polysaccharide Capsules of Escherichia coli K1 and Group B Meningococci," Proc. Natl. Acad. Sci. USA, 82:1194-1198 (1985).
Hornberger et al., "Human Monoclonal Antibodies Against Gram-Negative Bacteria," Fed. Am. Soc. Exp. Biol., 69th Ann. Meet., Abst. No. 5366, (1985).
Givner et al., "Immune Globulin for Intravenous Use: Enhancement of in Vitro Opsonophagocytic Activity of Neonatal Serum,"J. Infect. Dis. 151:217-220 (1985).
Pluschke et al., "Soium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis and Monoclonal Antibodies as Tools for the Subgrouping of Escherichia coli Lipopolysaccharide 018 and 023 Antigens," Infect. Immun., 51:286-293 (Jan., 1986).
Verhoef et al., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," Eur. J. Clin. Microbiol. Infect. Dis., 9:247-250 (Apr. 1990).
Osband et al., "Problems in the Investigation Study and Clinical Use of Cancer Immunotherapy," Immunology Today, 11:193-195 (1990).
Waldmann, "Monoclonal Antibodies in Diagnosis and Therapy," Science, 252:1657-1662 (Jun., 1991).
Fitzer-Schiller, "Centocor Stops Trials of Flagship Drug," The Washington Post, D3 (Jan. 19, 1993).
Stone, "Biotech Industry Reels on Sepsis Drug News," Science 25:1243 (Feb. 26, 1993).
Spaulding, "In Shocking Synergen, Sepsis Tallies Third Victim," Bio/Technology, 11:428-
Bristol--Myers Squibb Company
Loring Susan A.
LandOfFree
Cross-protective human monoclonal antibody compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cross-protective human monoclonal antibody compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cross-protective human monoclonal antibody compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-883497